SOUTH SAN FRANCISCO, CA, Apr 19, 2012 (MARKETWIRE via COMTEX) --Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that it
is scheduled to report first quarter results on Thursday, April 26,
2012 at 4:00 PM Eastern Time. Following the announcement,
Cytokinetics' senior management will host a conference call at 4:30
PM Eastern Time to discuss operational and financial results and the
company's outlook for the future.
The conference call will be simultaneously webcast and can be
accessed in the Investor Relations section of Cytokinetics' website
at www.cytokinetics.com. The live audio of the conference call can
also be accessed by telephone by dialing either (866) 999-CYTK (2985)
(United States and Canada) or (706) 679-3078 (international) and
typing in the passcode 21514127.
An archived replay of the webcast will be available via Cytokinetics'
website until May 3, 2012. The replay will also be available via
telephone by dialing (855) 859-2056 (United States and Canada) or
(404) 537-3406 (international) and typing in the passcode 21514127
from April 26, 2012 at 5:30 PM Eastern Time until May 3, 2012.
About Cytokinetics
Cytokinetics is a clinical-stage biopharmaceutical company focused on
the discovery and development of novel small molecule therapeutics
that modulate muscle function for the potential treatment of serious
diseases and medical conditions. Cytokinetics' lead drug candidate
from its cardiac muscle contractility program, omecamtiv mecarbil, is
in Phase II clinical development for the potential treatment of heart
failure. Amgen Inc. holds an exclusive license worldwide (excluding
Japan) to develop and commercialize omecamtiv mecarbil and related
compounds, subject to Cytokinetics' specified development and
commercialization participation rights. Cytokinetics is independently
developing CK-2017357, a skeletal muscle activator, as a potential
treatment for diseases and conditions associated with aging, muscle
wasting or neuromuscular dysfunction. CK-2017357 is currently the
subject of a Phase II clinical trials program and has been granted
orphan drug designation by the U.S. Food and Drug Administration and
orphan medicinal product designation by the European Medicines Agency
for the potential treatment of amyotrophic lateral sclerosis, a
debilitating disease of neuromuscular impairment in which CK-2017357
demonstrated potentially clinically relevant pharmacodynamic effects
in a Phase IIa trial. Cytokinetics is also conducting research of
compounds that inhibit smooth muscle contractility and which may be
useful as potential treatments for diseases and conditions associated
with excessive smooth muscle contraction, such as bronchoconstriction
associated with asthma and chronic obstructive pulmonary disorder
(COPD). All of these drug candidates and potential drug candidates
have arisen from Cytokinetics' research activities and are directed
towards the cytoskeleton. The cytoskeleton is a complex biological
infrastructure that plays a fundamental role within every human cell.
Additional information about Cytokinetics can be obtained at
www.cytokinetics.com.
This press release contains forward-looking statements for purposes
of the Private Securities Litigation Reform Act of 1995 (the "Act").
Cytokinetics disclaims any intent or obligation to update these
forward-looking statements, and claims the protection of the Act's
safe harbor for forward-looking statements. Examples of such
statements include, but are not limited to, statements relating to
planned presentations, and the properties and potential benefits of
Cytokinetics' drug candidates and potential drug candidates. Such
statements are based on management's current expectations, but actual
results may differ materially due to various risks and uncertainties,
including, but not limited to, potential difficulties or delays in
the development, testing, regulatory approval and production of
Cytokinetics' drug candidates and potential drug candidates that
could slow or prevent clinical development or product approval,
including risks that current and past results of clinical trials or
preclinical studies may not be indicative of future clinical trials
results and that Cytokinetics' drug candidates and potential drug
candidates may have unexpected adverse side effects or inadequate
therapeutic efficacy. For further information regarding these and
other risks related to Cytokinetics' business, investors should
consult Cytokinetics' filings with the Securities and Exchange
Commission.
Cytokinetics, Incorporated:
Jodi L. Goldstein
Manager, IR, Corporate Communications and Marketing
(650) 624-3000
SOURCE: Cytokinetics, Inc.
